Ontario Expands Trikafta Coverage to Patients as Young as 6 Years
The government of Ontario has expanded coverage of Vertex Pharmaceuticals’ triple-combination treatment Trikafta for children, 6 and older, with cystic fibrosis (CF) and at least one copy of the most common CF-causing mutation, called F508del. The announcement comes a few months after Health Canada expanded Trikafta’s previous label,…